GlassScriptPhysician profile
Zareena Abbas
NPI 1427078872
$4,656.49
in general payments reported to CMS, 2019-2025
36 companies · $828 in 2025
The $828 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $495 · 2021: $974 · 2022: $782 · 2023: $858 · 2024: $451 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.24 | 2019-2025 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $517.22 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $510.53 | 2019-2024 | |
| Lilly USA, LLC | $283.76 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $217.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.53 | 2019-2024 | Jardiance |
| Dexcom, INC. | $207.34 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $198.01 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Xeris Pharmaceuticals, INC. | $172.59 | 2021-2025 | Gvoke Hypopen |
| Pfizer INC. | $158.18 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $156.22 | 2019-2022 | |
| Corcept Therapeutics | $140.86 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $121.16 | 2021-2022 | |
| Amgen INC. | $116.49 | 2022-2025 | Krystexxa, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $105.96 | 2023-2025 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $98.02 | 2020-2021 | |
| Exact Sciences Corporation | $83.54 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.11 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $70.48 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $63.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $60.76 | 2020 | |
| Glaxosmithkline, LLC. | $47.08 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Ultragenyx Pharmaceutical INC. | $44.80 | 2019-2022 | |
| Scynexis, INC. | $33.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $31.35 | 2021-2024 | Rexulti |
| Abbvie INC. | $26.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.82 | 2023 | Eliquis |
| Horizon Therapeutics Plc | $22.90 | 2023 | Krystexxa |
| Allergan, INC. | $22.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.12 | 2025 | Zoryve |
| Astellas Pharma US INC | $19.52 | 2023 | Veozah |
| Mannkind Corporation | $18.10 | 2023 | Afrezza |
| Insulet Corporation | $16.27 | 2019 | |
| Evoke Pharma, INC. | $14.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.34 | 2024 | Voquezna |
| Snap Diagnostics LLC | $13.34 | 2024 | Snap Diagnostics Study |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zareena Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.